

October 17, 2025

To,  
The Listing Department,  
**BSE LIMITED,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai- 400 001

Scrip Code: 543349

To,  
The Listing Department  
**National Stock Exchange of India Limited,**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot no. C-1,  
G-Block, Bandra Kurla Complex,  
Mumbai -400051

NSE Symbol: ACUTAAS

**Subject: Unaudited Standalone & Consolidated Financial Results for the second quarter & half year ended September 30, 2025**

We would like to inform that the Board of Directors at its meeting held on October 17, 2025 inter alia, considered and approved the Unaudited Standalone and consolidated Financial Results for the second quarter & half year ended September 30, 2025 as recommended by the Audit Committee. The Board also took note of the 'Limited Review Report' issued by the Company's Statutory Auditors, M/s. Maheshwari & Co. Chartered Accountants. We enclose herewith the following:

1. Statement showing the Unaudited Standalone & Consolidated Financial Results for the quarter and half year ended September 30, 2025.
2. Standalone & Consolidated Balance Sheet as on 30<sup>th</sup> September, 2025.
3. Standalone and Consolidated Cash Flow Statement for the half year ended 30<sup>th</sup> September, 2025.
4. Limited Review Report on standalone and consolidated financial statements issued by the Statutory Auditors of the Company.

As required under Regulation 47 (1) (b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the extract of the Financial Results will be published in the newspapers in the format prescribed by SEBI. The Financial Results will also be available on the Company's website at [www.acutaas.com](http://www.acutaas.com).

Kindly take above as compliance of Regulation 33 and 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11.00 A.M. and concluded at **11.50 A.M**

Thanking you,

For, ACUTAAS CHEMICALS LIMITED

**Ekta Kumari Srivastava**  
Company Secretary & Compliance Officer



Encl: As above

**Independent Auditor's Review Report on Review of Interim Standalone Financial Results**

**To The Board of Directors,  
Acutaas Chemicals Limited (formerly known as Ami Organics Limited)**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Acutaas Chemicals Limited ('hereinafter referred to as "the Company") for the quarter and half year ended September 30, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listed Regulations")
2. This Statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ("Ind AS 34") and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard ("Ind AS 34") and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Maheshwari & Co.**  
**Chartered Accountants**  
**Firm's Registration No.: 105834W**



  
**Vikas Asawa**  
**Partner**

**Membership No.: 172133**  
**UDIN: 25172133BMIAJY8948**

**Place: Mumbai**  
**Date: October 17, 2025**

**Office:** 1302/1303, Solaris One, Vijay Nagar, Opp. Teli Gali, Andheri (East), 400069

**Head office:** 10-11, Third Floor, Esplanade Building, 3 A K Naik Marg (Bestian Road), Near New Empire Cinema, Fort, CST, Mumbai 400 001  
**Tel.:** +91-22-22077472/22072620, **E-mail:** vkasawa@maheshwariandco.in, **Website:** [www.maheshwariandco.in](http://www.maheshwariandco.in)

# ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

## Standalone Financial Results for the Quarter & Half Year Ended September 30, 2025

(₹ in lakhs, unless otherwise stated)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Income</b>						
Revenue from operations	30,519.34	20,597.09	24,359.20	51,116.43	41,472.90	98,983.46
Other income	896.95	1,602.01	857.77	2,498.96	1,047.50	1,833.56
<b>Total Income</b>	<b>31,416.29</b>	<b>22,199.10</b>	<b>25,216.97</b>	<b>53,615.39</b>	<b>42,520.40</b>	<b>100,817.02</b>
<b>Expenses</b>						
Cost of materials consumed	13,002.56	10,317.71	14,165.88	23,320.27	24,629.92	56,684.02
Changes in inventories of finished goods, stock-in-trade and work-in-progress	513.51	(654.23)	(273.10)	(140.72)	(654.69)	(1,864.56)
Employee benefits expense	2,863.88	2,440.25	1,896.31	5,304.13	3,741.95	8,094.72
Finance costs	57.20	61.96	49.36	119.16	486.63	585.74
Depreciation and amortization expense	772.24	746.21	619.56	1,518.45	1,181.70	2,404.52
Other expenses	4,478.76	3,394.50	3,757.02	7,873.26	6,312.83	13,555.05
<b>Total expenses</b>	<b>21,688.15</b>	<b>16,306.40</b>	<b>20,215.03</b>	<b>37,994.55</b>	<b>35,698.34</b>	<b>79,459.49</b>
<b>Profit/(loss) before exceptional items and tax</b>	<b>9,728.14</b>	<b>5,892.70</b>	<b>5,001.94</b>	<b>15,620.84</b>	<b>6,822.06</b>	<b>21,357.53</b>
Exceptional items	-	-	-	-	-	-
<b>Profit/(loss) before tax</b>	<b>9,728.14</b>	<b>5,892.70</b>	<b>5,001.94</b>	<b>15,620.84</b>	<b>6,822.06</b>	<b>21,357.53</b>
<b>Tax expense</b>						
Current tax	1,935.20	1,272.82	1,185.25	3,208.02	1,547.08	4,697.08
Deferred tax	503.78	155.26	48.87	659.04	135.57	705.83
<b>Total tax expense</b>	<b>2,438.98</b>	<b>1,428.08</b>	<b>1,234.12</b>	<b>3,867.06</b>	<b>1,682.65</b>	<b>5,402.91</b>
<b>Profit for the period</b>	<b>7,289.16</b>	<b>4,464.62</b>	<b>3,767.82</b>	<b>11,753.78</b>	<b>5,139.41</b>	<b>15,954.62</b>
<b>Other comprehensive Income (OCI)</b>						
Items that will not be reclassified to profit or loss						
Remeasurement of defined employee benefit plans	(39.97)	(3.65)	(37.91)	(43.62)	(41.00)	(14.59)
Tax impact on items that will not be reclassified to profit or loss	10.06	0.92	9.54	10.98	10.32	3.67
<b>Total other comprehensive income (net of tax)</b>	<b>(29.91)</b>	<b>(2.73)</b>	<b>(28.37)</b>	<b>(32.64)</b>	<b>(30.68)</b>	<b>(10.92)</b>
<b>Total comprehensive Income for the period</b>	<b>7,259.25</b>	<b>4,461.89</b>	<b>3,739.45</b>	<b>11,721.14</b>	<b>5,108.73</b>	<b>15,943.70</b>
<b>Details of equity share capital</b>	<b>4,093.56</b>	<b>4,093.45</b>	<b>4,092.75</b>	<b>4,093.56</b>	<b>4,092.75</b>	<b>4,093.45</b>
Equity shares of face value Rs. 5/- each						
<b>Other equity</b>						<b>127,066.07</b>
<b>Earnings per equity share of ₹ 5/- each ( not annualised, excluding year end )</b>						
Basic (₹)	8.90	5.45	4.70	14.36	6.42	19.91
Diluted (₹)	8.90	5.45	4.70	14.36	6.42	19.91

For Acutaas Chemicals Limited

Date: Oct 17, 2025

Place: Surat



*(Signature)*

**Nareshkumar Ram/ibhal Patel**  
Chairman & Managing Director

DIN: 00906232

# ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Standalone Balance Sheet as at September 30, 2025

₹ in Lakhs

Particulars	As at	
	September 30, 2025	March 31, 2025
	Unaudited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	56,069.37	45,380.90
Capital work-in-progress	12,474.88	13,028.41
Right-of-use assets	4,951.95	4,210.47
Intangible assets	298.36	331.50
<b>Financial Assets</b>		
i) Investments	11,902.58	6,979.79
ii) Loans	1,001.82	330.36
iii) Other financial assets	803.37	1,235.59
Income tax assets (net)	-	-
Other non-current assets	3,344.54	5,167.12
<b>Total non-current Assets</b>	<b>90,846.87</b>	<b>76,664.14</b>
<b>Current assets</b>		
Inventories	18,484.80	17,400.12
<b>Financial assets</b>		
i) Trade receivables	29,153.95	28,921.19
ii) Cash and cash equivalents	16,917.27	18,460.70
iii) Bank balances other than cash and cash equivalents	5,846.83	5,611.76
iv) Loans	208.19	214.58
Other current assets	5,629.52	6,522.98
<b>Total current assets</b>	<b>76,240.56</b>	<b>77,131.33</b>
<b>Total assets</b>	<b>167,087.43</b>	<b>153,795.47</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4,093.56	4,093.45
Other equity	137,566.46	127,066.07
<b>Total equity</b>	<b>141,660.02</b>	<b>131,159.52</b>
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
i) Borrowings	-	-
ii) Lease liabilities	814.79	475.44
<b>Provisions</b>	299.95	220.65
Deferred tax liabilities (net)	2,683.97	2,035.91
<b>Total non-current liabilities</b>	<b>3,798.71</b>	<b>2,732.00</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
i) Borrowings	-	634.90
ii) Trade Payables		
a) Total outstanding dues of micro enterprises and small enterprises	5,426.98	5,432.27
b) Total outstanding dues of other than micro enterprises and small enterprises	9,377.85	10,121.37
<b>Provisions</b>	3,197.15	2,408.11
Other current liabilities	3,250.91	1,305.51
Current tax liabilities (net)	375.81	1.79
<b>Total current liabilities</b>	<b>21,628.70</b>	<b>19,903.95</b>
<b>Total liabilities</b>	<b>25,427.41</b>	<b>22,635.95</b>
<b>Total equity and liabilities</b>	<b>167,087.43</b>	<b>153,795.47</b>





# ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Standalone Statement of Cash Flow for the period ended September 30, 2025

₹ in Lakhs

Particulars		For The Period Ended	
		September 30, 2025	September 30, 2024
		Unaudited	Unaudited
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before tax		15,620.84	6,822.06
<b>Adjustments for:</b>			
Depreciation and amortisation		1,518.45	1,181.70
(Gain)/loss on disposal of property, plant and equipment		(1.03)	(0.96)
Bad debts, provision for trade receivables and advances		-	142.01
Finance cost		119.16	486.63
Interest Income		(636.37)	(447.19)
Share of profit from partnership firm		77.21	(120.72)
Employee compensation expenses		6.28	93.66
Unrealised (gain) / loss		(1,937.57)	(478.58)
<b>Operating profit before working capital changes</b>		<b>14,766.97</b>	<b>7,678.61</b>
<b>Movement in working capital</b>			
(Increase) / decrease in trade receivables		1,704.81	(3,179.02)
(Increase) / decrease in loans & advances		(665.07)	(118.06)
(Increase) / decrease in other financial assets		432.22	(157.93)
(Increase) / decrease in inventories		(1,084.68)	(26.25)
(Increase) / decrease in other current assets		893.46	101.44
Increase / (decrease) in trade payables		(748.81)	1,420.92
Increase / (decrease) in other liabilities		536.14	(121.91)
Increase / (decrease) in provisions		824.72	885.19
<b>Cash generated/(used) In operations</b>		<b>16,659.76</b>	<b>6,482.99</b>
Income tax paid (net)		(2,834.00)	(1,781.12)
<b>Net cash (used)/generated by operating activities</b>	<b>(A)</b>	<b>13,825.76</b>	<b>4,701.87</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Investment in fixed deposit not considered as cash or cash equivalents		(235.07)	(21,024.42)
Purchase of property, plant and equipment			
(including CWIP, intangible assets and capital advances)		(10,022.69)	(8,518.56)
Purchase of investment		(5,000.00)	(120.72)
Dividend received		-	-
Proceeds from partnership firm		-	120.72
Interest received		636.37	447.19
<b>Net cash (used in) /generated by investing activities</b>	<b>(B)</b>	<b>(14,621.40)</b>	<b>(29,095.79)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Net proceeds / (repayment) from short term borrowings		(634.90)	(8,793.24)
Net proceeds / (repayment) from long term borrowings		-	(11,106.49)
Finance cost		(95.90)	(486.63)
Repayment of lease liabilities		(18.09)	-
Dividend paid		-	(1,227.83)
Issue of equity shares		1.10	49,931.94
Share application money pending allotment		-	8.17
Share issue expense		-	(1,094.77)
<b>Net cash (used)/generated in financing activities</b>	<b>(C)</b>	<b>(747.79)</b>	<b>27,231.15</b>
<b>Net increase / (decrease) In cash and cash equivalents</b>	<b>(A+B+C)</b>	<b>(1,543.43)</b>	<b>2,837.23</b>
Cash and cash equivalents at the beginning of the Period		18,460.70	2,948.83
Exchange gain/loss on cash and cash equivalents		-	-
<b>Cash and cash equivalents at the end of the Period</b>		<b>16,917.27</b>	<b>5,786.06</b>



**Notes to the Unaudited Standalone Financial Results for the quarter | half year ended September 30, 2025**

1. The above unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 17, 2025. The Statutory Auditors of the Company have carried out a limited review of the standalone unaudited financial results for the quarter | half year ended September 30, 2025. Their limited review report does not have any modification.
2. The above unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.
3. As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others. it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.
4. The Board of Directors of the Company at their meeting held on February 21 2025, and the Shareholders through postal ballot passed on March 26, 2025 have approved the sub-division/ split of each equity share of face value of Rs.10/- (Rupees Ten only) each, fully paid-up, into (two) equity shares having face value of Rs. 5/- (Rupees five only) each, fully paid-up. The record date for the said sub-division/ split was April 25, 2025. The basic and diluted EPS disclosed above have been adjusted to give effect to such sub-division/split in accordance with requirements under Ind AS 33, Earnings per share.
5. Pursuant to Regulation 30 read with Schedule III of the Listing Regulations, Acutaas Chemicals Limited ("the Company") has on recommendation and approval of the Audit Committee & Board of Directors, made investment in Acutaas Advance Material Limited ("AAML") (formerly known as Baba Advance Materials Limited) up to an amount not exceeding Rs 49.99 crores by subscribing to 30,48,780 equity shares of Rs 10/- each, at a premium of Rs. 154/- per shares by way of rights issue of AAML and further investment not exceeding Rs. 150 crores by way of loan or equity subscription or mix of both, in one or more tranches in AAML, wholly owned subsidiary of the Company.
6. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation.
7. The results of the company are available at Company's website [www.acutaas.com](http://www.acutaas.com) and also on the website of BSE Limited at [www.bseindia.com](http://www.bseindia.com) and National Stock Exchange of India Limited at [www.nseindia.com](http://www.nseindia.com) where the shares of the Company are listed.



Date: October 17, 2025  
Place: Surat



For and behalf of Board of Directors of  
**Acutaas Chemicals Limited**  
(Formerly known as Ami Organics Limited)

**Nareshkumar Ramjibhai Patel**  
Chairman & Managing Director  
DIN: 00906232

**Independent Auditor's Review Report on Review of Interim Consolidated Financial Results**

**To The Board of Directors**

**Acutaas Chemicals Limited (formerly known as Ami Organics Limited)**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Acutaas Chemicals Limited ("the Parent") and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its associate and joint venture for the quarter and half year ended September 30, 2025 ("the Statement"), attached herewith, being submitted by the Parent pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulation 33 of the Listing Regulation. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the results of the following entities:
  - a. Holding Company: Acutaas Chemicals Limited
  - b. Wholly owned Subsidiary Company: Acutaas Chemicals Electrolytes Private Limited
  - c. Wholly owned Subsidiary Company: Acutaas Advance Materials Limited
  - d. Subsidiary: Baba Fine Chemicals (Partnership Firm)
  - e. Joint Venture: Ami Onco-Theronostics, LLC
  - f. Step down subsidiary: Enchem Ami Organics Private Limited
  - g. Step down subsidiary: Indichem Inc.
5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard ("Ind AS 34") and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**For Maheshwari & Co.**  
**Chartered Accountants**  
**Firm's Registration No.: 105834W**

**Vikas Asawa**  
**(Partner)**  
**Membership No.: 172133**

**Place: Mumbai**  
**Date: October 17, 2025**

**UDIN: 25172133BMIAJZ8107**

**Office: 1302/1303, Solaris One, Vijay Nagar, Opp. Teli Gali, Andheri (East), 400069**

**Head office: 10-11, Third Floor, Esplanade Building, 3 A K Naik Marg (Bestian Road), Near New Empire Cinema, Fort, CST, Mumbai 400 001**  
**Tel.: +91-22-22077472/22072620, E-mail: vkasawa@maheshwariandco.in, Website: [www.maheshwariandco.in](http://www.maheshwariandco.in)**



**ACUTAAS CHEMICALS LIMITED**

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Address: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

**Consolidated Financial Results for the Quarter & Half Year Ended September 30, 2025**

(\* in lakhs, unless otherwise stated)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Income</b>						
Revenue from operations	30,619.58	20,723.72	24,673.36	51,343.30	42,340.45	100,687.55
Other income	983.73	1,593.77	843.65	2,577.50	947.91	1,692.94
<b>Total Income</b>	<b>31,603.31</b>	<b>22,317.49</b>	<b>25,517.01</b>	<b>53,920.80</b>	<b>43,288.36</b>	<b>102,380.49</b>
<b>Expenses</b>						
Cost of materials consumed	13,123.89	10,406.01	14,299.41	23,529.90	24,804.92	56,981.13
Changes in inventories of finished goods, stock-in-trade and work-in-progress	421.26	(716.98)	(344.08)	(295.72)	(616.31)	(1,762.96)
Employee benefits expense	2,935.34	2,507.33	1,963.27	5,442.67	3,868.87	8,365.59
Finance costs	57.87	63.85	50.27	121.72	492.91	621.84
Depreciation and amortization expense	840.16	813.08	682.53	1,653.24	1,300.45	2,662.14
Other expenses	4,606.81	3,436.63	3,861.57	8,043.44	6,438.05	13,896.45
<b>Total expenses</b>	<b>21,985.33</b>	<b>16,509.92</b>	<b>20,512.97</b>	<b>38,495.25</b>	<b>36,288.89</b>	<b>80,764.19</b>
<b>Profit before exceptional items and tax</b>	<b>9,617.98</b>	<b>5,807.57</b>	<b>5,004.04</b>	<b>15,425.55</b>	<b>6,999.47</b>	<b>21,616.30</b>
Exceptional items	-	-	-	-	-	-
<b>Profit before tax</b>	<b>9,617.98</b>	<b>5,807.57</b>	<b>5,004.04</b>	<b>15,425.55</b>	<b>6,999.47</b>	<b>21,616.30</b>
<b>Tax expense</b>						
Current tax	1,926.34	1,272.82	1,211.74	3,199.16	1,665.09	4,918.95
Deferred tax	506.05	133.70	35.63	639.75	108.74	655.58
<b>Total tax expense</b>	<b>2,432.39</b>	<b>1,406.52</b>	<b>1,247.37</b>	<b>3,838.91</b>	<b>1,773.83</b>	<b>5,574.53</b>
<b>Profit for the period</b>	<b>7,185.59</b>	<b>4,401.05</b>	<b>3,756.67</b>	<b>11,586.64</b>	<b>5,225.64</b>	<b>16,041.77</b>
<b>Other comprehensive income</b>						
Items that will not be reclassified to profit or loss						
Remeasurement of defined employee benefit plans	(38.09)	(4.37)	(36.87)	(42.46)	(38.54)	(17.48)
Tax impact on items that will not be reclassified to profit or loss	10.06	0.92	9.28	10.98	9.70	3.67
<b>Other comprehensive income</b>	<b>(28.03)</b>	<b>(3.45)</b>	<b>(27.59)</b>	<b>(31.48)</b>	<b>(28.84)</b>	<b>(13.81)</b>
<b>Total comprehensive income for the period</b>	<b>7,157.56</b>	<b>4,397.60</b>	<b>3,729.08</b>	<b>11,555.16</b>	<b>5,196.80</b>	<b>16,027.96</b>
<b>Profit attributable to</b>						
Owners of the company	7,224.06	4,429.34	3,733.18	11,653.40	5,127.70	15,871.36
Non - controlling interest	(38.47)	(28.29)	23.49	(66.76)	97.94	170.41
<b>Other comprehensive income attributable to</b>						
Owners of the company	(28.88)	(3.12)	(27.94)	(32.00)	(29.67)	(12.51)
Non - controlling interest	0.85	(0.33)	0.35	0.52	0.83	(1.30)
<b>Paid up equity share capital (face value of ₹ 5 each)</b>	<b>4,093.56</b>	<b>4,093.45</b>	<b>4,092.75</b>	<b>4,093.56</b>	<b>4,092.75</b>	<b>4,093.45</b>
<b>Other equity</b>						<b>126,869.42</b>
<b>Earnings per equity share of ₹ 5 each (not annualised, excluding year end)</b>						
Basic (₹)	8.82	5.41	4.69	14.23	6.53	19.81
Diluted (₹)	8.82	5.41	4.69	14.23	6.53	19.81

For Acutaas Chemicals Limited

Date: Oct 17, 2025  
Place: Surat  
Nareshkumar Ramjibhai Patel  
Chairman & Managing Director  
DIN: 00906232



# ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Consolidated Balance Sheet as at September 30, 2025

₹ in Lakhs

Particulars	As at	
	September 30, 2025	March 31, 2025
	Unaudited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	56,979.94	46,292.28
Capital work-in-progress	15,193.29	13,028.40
Right-of-use assets	4,980.37	4,239.03
Goodwill	7,332.62	5,680.09
Intangible assets	732.37	827.51
Intangible assets under development	-	-
<b>Financial Assets</b>		
i) Investments	19.53	19.53
ii) Other financial assets	690.79	493.24
Income tax assets (net)	-	15.31
Other non-current assets	4,647.56	5,167.12
<b>Total non-current assets</b>	<b>90,576.48</b>	<b>75,762.51</b>
<b>Current assets</b>		
Inventories	19,098.43	17,994.02
<b>Financial assets</b>		
i) Trade receivables	29,147.84	29,049.47
ii) Cash and cash equivalents	17,246.07	18,522.43
iii) Bank balances other than cash and cash equivalents	6,817.74	6,370.40
iv) Loans	214.28	215.98
Other current assets	6,463.67	7,011.30
<b>Total current assets</b>	<b>78,988.03</b>	<b>79,163.60</b>
<b>Total assets</b>	<b>169,564.51</b>	<b>154,926.11</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4,093.56	4,093.45
Other equity	137,270.06	126,869.42
<b>Equity attributable to owners of the Company</b>	<b>141,363.62</b>	<b>130,962.87</b>
Non controlling interests	2,542.96	1,045.17
<b>Total equity</b>	<b>143,906.58</b>	<b>132,008.04</b>
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
i) Borrowings	-	-
ii) Lease liabilities	814.79	475.44
Provisions	334.90	254.64
Deferred tax liabilities (net)	2,592.63	1,963.25
<b>Total non-current liabilities</b>	<b>3,742.32</b>	<b>2,693.33</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
i) Borrowings	20.08	818.43
ii) Trade payables		
a) Total outstanding dues of micro enterprises and small enterprises	5,426.98	5,432.27
b) Total outstanding dues of other than micro enterprises and small enterprises	9,492.83	10,172.30
Other current liabilities	3,441.53	1,347.74
Provisions	3,205.85	2,454.00
Current tax liabilities (net)	328.34	
<b>Total current liabilities</b>	<b>21,915.61</b>	<b>20,224.74</b>
<b>Total liabilities</b>	<b>25,657.93</b>	<b>22,918.07</b>
<b>Total equity and liabilities</b>	<b>169,564.51</b>	<b>154,926.11</b>



# ACUTAAS CHEMICALS LIMITED

(Formerly known as Ami Organics Limited)

CIN: L24100GJ2007PLC051093

Registered office: 440/4 5 6, Road No 82A, Sachin GIDC, Surat, Gujarat - 394 230, India

Tel: +91 72279 77744; +91 75730 15366

Website: www.acutaas.com Email: cs@acutaas.com

Consolidated Statement of Cash Flow for the period ended September 30, 2025

₹ in Lakhs

Particulars		For The Period Ended	
		September 30, 2025	September 30, 2024
		Unaudited	Unaudited
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before Tax		15,425.55	6,999.47
<b>Adjustments for:</b>			
Depreciation and amortisation		1,653.24	1,300.45
(Gain)/Loss on disposal of property, plant and equipment		(1.03)	(0.96)
Bad debts, provision for trade receivables and advances		-	142.01
Interest paid		121.72	506.06
Interest Income		(638.18)	(477.90)
ESOS compensation expenses		6.28	93.66
Unrealised (gain) / loss		(1,938.29)	(483.27)
<b>Operating profit before working capital changes</b>		<b>14,629.29</b>	<b>8,079.44</b>
<b>Movement in working capital</b>			
(Increase) / decrease in trade receivables		1,839.92	(3,312.46)
(Increase) / decrease in loans & advances		1.70	(118.06)
(Increase) / decrease in other financial assets		(197.55)	(156.13)
(Increase) / decrease in inventories		(1,104.41)	(80.15)
(Increase) / decrease in other current assets		547.63	136.36
Increase / (decrease) in trade payables		(684.76)	1,257.60
Increase / (decrease) in other liabilities		684.53	(105.22)
Increase / (decrease) in provisions		789.65	900.61
<b>Cash generated from operations</b>		<b>16,506.00</b>	<b>6,601.99</b>
Income tax paid (net)		(2,855.51)	(1,973.67)
<b>Net cash (used)/generated by operating activities</b>	<b>(A)</b>	<b>13,650.49</b>	<b>4,628.32</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Investment in fixed deposit not considered as cash or cash equivalents		(447.34)	(19,773.98)
Purchase of property, plant and equipment (including CWIP, intangible assets and including capital advances)		(14,115.38)	(7,901.10)
Right of Use Asset		-	(46.05)
Incidental Charges towards purchase of Investment		(88.51)	-
Change in other non current assets		-	(674.87)
Interest received		638.18	477.98
<b>Net cash (used in) / generated by investing activities</b>	<b>(B)</b>	<b>(14,013.04)</b>	<b>(27,918.02)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Net Proceeds / (Repayment) from long term borrowings		-	(11,106.47)
Net Proceeds / (Repayment) from short term borrowings		(798.35)	(9,869.08)
Interest paid		(98.46)	(506.06)
Repayment of lease liabilities		(18.09)	-
Dividend paid (including tax on dividend)		-	(1,227.83)
Issue of equity shares		1.10	49,931.94
Share application money pending allotment		-	8.17
Share issue expense		-	(1,094.76)
<b>Net cash (used)/generated in financing activities</b>	<b>(C)</b>	<b>(913.80)</b>	<b>26,135.91</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>(A+B+C)</b>	<b>(1,276.35)</b>	<b>2,846.21</b>
Cash and cash equivalents at the beginning of the Period		18,522.43	2,970.43
Exchange gain loss on Cash and cash equivalents		-	-
<b>Cash and cash equivalents at the end of the Period</b>		<b>17,246.07</b>	<b>5,816.64</b>



## Notes to the Unaudited Consolidated Financial Results for the quarter | half year ended September 30, 2025

1. The above unaudited consolidated financial results for the quarter | half year ended September 30, 2025, which includes the financial information of Acutaas Chemicals Limited (Formerly known as Ami Organics Limited) ("the Company"), its subsidiary entities namely, Acutaas Chemicals Electrolytes Private Limited (formerly known as Ami Organics Electrolytes Private Limited), Acutaas Advance Materials Limited (formerly known as Baba Advance Materials Limited) and Baba Fine Chemicals (collectively "the group"), its step down subsidiary entities namely, Enchem Ami Organics Private Limited and Indichem Inc. and its joint venture namely, Ami Onco-Theranostics LLC, were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 17, 2025. The Statutory Auditors of the Company have carried out a limited review of the consolidated unaudited financial results for the quarter | half year ended on September 30, 2025. Their limited review report does not have any modification.
2. The above unaudited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.
3. As the Company operates in Single Segment only i.e. Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others. it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.
4. The Board of Directors of the Company at their meeting held on February 21 2025, and the Shareholders through postal ballot passed on March 26, 2025 have approved the sub-division/ split of each equity share of face value of Rs.10/- (Rupees Ten only) each, fully paid-up, into (two) equity shares having face value of Rs. 5/- (Rupees five only) each, fully paid-up. The record date for the said sub-division/ split was April 25, 2025. The basic and diluted EPS disclosed above have been adjusted to give effect to such sub-division/split in accordance with requirements under Ind AS 33, Earnings per share.
5. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Registrar of Companies, Ministry of Corporate Affairs has approved the following name changes:
  - Two wholly-owned subsidiary companies have also undergone a name change:
    - Baba Advance Materials Limited has been renamed Acutaas Advance Material Limited, effective July 17, 2025.
    - Ami Organics Electrolytes Private Limited has been renamed Acutaas Chemicals Electrolytes Private Limited, effective July 28, 2025.
6. In accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Acutaas Advance Materials Limited ("AAML") (formerly known as Baba Advance Materials Limited), wholly owned subsidiary company of Acutaas Chemicals Limited has entered into a joint venture agreement with J & Materials Co. Ltd., a South Korean Company, whereby AAML shall hold 75% of the share capital of the joint venture company Indichem Inc. ("JV Company") a South Korean Company and the remaining 25% of the share capital of the JV Company will be held by J & Materials Co. Ltd., effectively from June 27, 2025. With reference to this and pursuant to Regulation 30 read with Schedule III of the Listing Regulations, Acutaas Chemicals Limited ("the Company") has on recommendation and approval of the Audit Committee & Board of Directors, made investment in Acutaas Advance Material Limited ("AAML") (formerly known as Baba Advance Materials Limited) up to an amount not exceeding Rs 49.99 crores by subscribing to 30,48,780 equity shares of Rs 10/- each, at a premium of Rs. 154/- per shares by way of rights issue of AAML and further investment not exceeding Rs. 150 crores by way of loan or equity subscription or mix of both, in one or more tranches in AAML, wholly owned subsidiary of the Company.
7. Acutaas Advance Material Limited ("AAML"), a joint venture company, has made an investment of Rs. 44.68 crores in Indichem Inc. ("JV Company") by way of subscription to the equity shares of the said company in the quarter | half year ended September 30, 2025
8. The previous periods/year's numbers have been regrouped/ rearranged wherever necessary to confirm the current period/year presentation.



9. The results of the company are available at Company's website [www.acutaas.com](http://www.acutaas.com) and also on the website of BSE Limited at [www.bseindia.com](http://www.bseindia.com) and National Stock Exchange of India Limited at [www.nseindia.com](http://www.nseindia.com) where the shares of the Company are listed.



For and behalf of Board of Directors of  
**Acutaas Chemicals Limited**  
(Formerly known as Ami Organics  
Limited)

A handwritten signature in blue ink, appearing to read "Nareshkumar Ramjibhai Patel".

**Nareshkumar Ramjibhai Patel**  
Chairman & Managing Director  
DIN: 00906232

Date: October 17, 2025  
Place: Surat